From: Arbaclofen in fragile X syndrome: results of phase 3 trials
Group/characteristic | Placebo (N = 63) | Arbaclofen (N = 62) | Total (N = 125) |
---|---|---|---|
Mean age (SD) | 18.7 (7.22) | 19.0 (6.73) | 18.9 (6.96) |
Age group (adolescents age 12–17) | 36 (57.1%) | 31 (50.0%) | 67 (53.6%) |
Gender (males) | 49 (77.8%) | 50 (80.6%) | 99 (79.2%) |
 Race/ethnicity |  |  |  |
 White non-hispanic | 50 (79%) | 47 (76%) | 97 (77%) |
 White hispanic | 4 (6.5%) | 5 (8.1%) | 9 (7.2%) |
 African American | 6 (9.5%) | 5 (8.1%) | 11 (8.8%) |
 Asian | 1 (1.6%) | 1 (1.6%) | 2 (1.6%) |
 Other | 2 (3.2%) | 4 (6.5%) | 6 (4.8%) |
Concomitant medications | Â | Â | Â |
 Any psychotropic medications | 40 (63.5%) | 35 (56.5%) | 75 (60.0%) |
 Antipsychotics | 11 (17.4%) | 14 (22.6%) | 25 (20.0%) |
 None | 23 (36.5%) | 27 (43.5%) | 50 (40.0%) |
DSM-IV diagnosis of ASD | 45 (71.4%) | 46 (74.2%) | 91 (72.8%) |
Mean ABC-CFX Social Avoidance score (SD) | 7.9 (3.48) | 7.6 (3.17) | Â |